Promore Pharma AB (publ) has received approval for continued trading on Nasdaq First North Growth Market and publishes company description

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

STOCKHOLM, SWEDEN / ACCESSWIRE / December 21, 2023 / Promore Pharma (STO:PROMO) (FRA:8T0) Promore Pharma AB (publ), under name change to PMD Device Solutions AB (the “Company”), has received approval for continued trading on Nasdaq First North Growth Market and publishes a company description prepared in connection with the name and business change of the Company as a result of the planned acquisition of PMD Device Solutions AB.

On 29 November 2023, the Company announced the reverse acquisition of PMD Device Solutions AB, subject to resolution by the extraordinary general meeting of the Company on 29 December 2023 (the “Reverse Acquisition”). The Company has today received approval from Nasdaq Stockholm for continued trading on Nasdaq First North Growth Market, subject to customary conditions. The Company also publishes a company description due to the Reverse Acquisition and the continued listing. The company description is available at www.promorepharma.com.

Information about PMD
PMD develops and sells medical products for respiratory monitoring. Its primary product is RespiraSense™, a solution used for monitoring respiratory rate to detect deterioration of a patient’s general condition early and to avoid preventable respiratory failure and adverse patient outcomes. RespiraSense™ is, to the PMD’s knowledge, the world’s only continuous, motion-tolerant respiratory rate monitor delivering class-leading reliability in measuring respiratory rate. PMD received FDA approval for RespiraSense™ in 2022. RespiraSense™ is a novel technology and today used in 25 hospitals across United Kingdom and Ireland. PMD seeks to continue increasing its market share in the United Kingdom, with Germany and the United States to follow with initial market access activities.

For additional information, please contact:

Lars-Henrik Andersson, liquidator
Phone: [+46] 8 527 91 600
E-mail: Lars-Henrik.Andersson@cirio.se

Promore Pharma’s Certified Adviser is Redeye

Promore Pharma in brief

Promore Pharma is a biopharmaceutical company specialized in the development of locally administered first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. The company is listed on Nasdaq First North Growth Market.

Attachments

Promore Pharma AB (publ) has received approval for continued trading on Nasdaq First North Growth Market and publishes company description

SOURCE: Promore Pharma

View the original press release on accesswire.com

Staff

Recent Posts

lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics

SAN DIEGO, June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments…

2 hours ago

Applied Medical Technology, Inc. Unveils Redesigned Mobile App Aligned with Recent Website Refresh

BRECKSVILLE, Ohio., June 10, 2025 /PRNewswire/ -- Applied Medical Technology, Inc. (AMT), a leader in innovative…

2 hours ago

NCPDP Foundation Awards $200,000 Grant to CARIN Alliance for Consumer-Facing Real-Time Pharmacy Benefit Check Project

SCOTTSDALE, Ariz., June 10, 2025 /PRNewswire/ -- The NCPDP Foundation is pleased to announce the approval…

2 hours ago

CSD Charts a New Course for Career Growth with Launch of Career Rewards

Milestone recognition, mentorship, and advancement opportunities come together as part of the Career Compass initiative…

2 hours ago

The YMCA of Metropolitan Chicago Names Adam M. Alonso as Next President and CEO

Veteran nonprofit executive and youth development champion Adam M. Alonso named President and CEO of…

2 hours ago

Santa Clara Family Health Plan renews partnership with Ushur, Inc., to better serve members through targeted digital text messaging

SAN JOSÉ, Calif., June 10, 2025 /PRNewswire/ -- Santa Clara Family Health Plan (SCFHP) is proud…

2 hours ago